Compare Sherwin-Williams Company (The) Common Stock (SHW) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sherwin-Williams Company (The) Common Stock vs 10X Genomics Inc — how do they compare? Sherwin-Williams Company (The) Common Stock trades at $327.77 (market cap $78.68B), while 10X Genomics Inc trades at $71.65 (market cap $9.35B). The key difference: Sherwin-Williams Company (The) Common Stock is far larger — about 8.4× 10X Genomics Inc's market cap, and Sherwin-Williams Company (The) Common Stock pays a 0.99% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| SHW | TXG | |
|---|---|---|
Market Cap | $78.68B | $9.35B |
Volume | 1,245,324 | 4,039,449 |
Sector | Basic Materials | Health |
52-Week High | $372.60 | $97.74 |
52-Week Low | $293.00 | $11.83 |
Enterprise Value | $92.60B | $8.88B |
Dividend Yield | 0.99% | — |
Typical Hold Time | — | 91 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sherwin-Williams (SHW) trades at $324.10, up 1.21% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows neutral technical signals but maintains robust fundamentals with 65.12% ROE and expanding manufacturing capacity. Recent facility expansions in Statesville enhance production capabilities, positioning the company for continued market share gains.
Outlook remains positive with analyst consensus at Buy (57.9%) and $383.64 price target, though high valuation multiples (P/E 29.9) and competitive pressures present risks. Earnings growth and strategic investments support upside potential, while margin compression and economic sensitivity warrant monitoring.
TXG trades at $73.10, down 2.78% on the day, with a bearish technical signal and neutral oscillators. The company reported revenue of $642.82M in 2025 but a net loss of $43.54M, though recent quarters show earnings beats. Analyst consensus is mixed with a $83.30 price target. Positive news includes Atera shipments and a patent victory, but profitability remains a challenge.
The outlook hinges on Atera's commercial success driving future revenue growth and margin improvement. Risks include persistent losses, competitive pressures, and execution delays. Upside potential exists if new platforms gain traction, but investors should weigh high valuation multiples against ongoing unprofitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sherwin-Williams Company (The) Common Stock
The Sherwin-Williams Company manufactures, develops, and distributes paints, coatings, and related products through three segments: Paint Stores Group, operating more than 4,900 company-owned stores selling Sherwin-Williams-branded products; Consumer Brands Group, selling brands such as Valspar, Dutch Boy, Krylon, and Minwax through mass merchandisers and home centers; and Performance Coatings Group, supplying industrial, construction, and transportation coatings in more than 120 countries.
Read more on SHW →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
